KZR Key Statistics, Chart & Performance
The current stock price of KZR is 6.5 USD. In the past month the price increased by 4%. In the past year, price decreased by -0.15%.
KZR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About KZR
Company Profile
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Company Info
KEZAR LIFE SCIENCES INC
4000 Shoreline Ct Ste 300
South San Francisco CALIFORNIA 94080 US
CEO: John Fowler
Employees: 55
Phone: 16508225600
KEZAR LIFE SCIENCES INC / KZR FAQ
What does KZR do?
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
What is the current price of KZR stock?
The current stock price of KZR is 6.5 USD. The price increased by 3.17% in the last trading session.
Does KZR stock pay dividends?
KZR does not pay a dividend.
What is the ChartMill technical and fundamental rating of KZR stock?
KZR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is KEZAR LIFE SCIENCES INC (KZR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KZR.
What is the outstanding short interest for KEZAR LIFE SCIENCES INC?
The outstanding short interest for KEZAR LIFE SCIENCES INC (KZR) is 3.94% of its float.
KZR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KZR. When comparing the yearly performance of all stocks, KZR is one of the better performing stocks in the market, outperforming 85.4% of all stocks.
KZR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KZR. KZR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KZR Financial Highlights
Over the last trailing twelve months KZR reported a non-GAAP Earnings per Share(EPS) of -8.44. The EPS increased by 34.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.55% | ||
| ROE | -77.93% | ||
| Debt/Equity | 0.03 |
KZR Forecast & Estimates
10 analysts have analysed KZR and the average price target is 6.12 USD. This implies a price decrease of -5.85% is expected in the next year compared to the current price of 6.5.